RANK/RANKL: Regulators of immune responses and bone physiology

Annals of the New York Academy of Sciences

Volumn 1143, Issue , 2008, Pages 123-150

  Leibbrandt, Andreas ^a   Penninger, Josef M ^a,b  

^a INSTITUTE OF MOLECULAR BIOTECHNOLOGY   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Lymph node formation; Mammary gland biology; OPG; Osteoclastogenesis; Osteoimmunology; Osteoporosis; RANK; RANK RANKL signaling; RANKL; Rheumatoid arthritis

Indexed keywords

AUTOIMMUNE REGULATOR PROTEIN; BETA INTERFERON; CALCINEURIN; CALCIUM; DENOSUMAB; GAMMA INTERFERON; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN BETA; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

AMINO ACID SEQUENCE; B LYMPHOCYTE; BINDING AFFINITY; BONE ATROPHY; BONE DEVELOPMENT; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; BREAST DEVELOPMENT; CELL FUNCTION; CELL MATURATION; CELL SURVIVAL; CLINICAL TRIAL; DENDRITIC CELL; DRUG TARGETING; ENZYME ACTIVATION; EXTRAMEDULLARY HEMATOPOIESIS; FUNCTIONAL PROTEOMICS; HOMEOSTASIS; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCHEMISTRY; IMMUNOREGULATION; LIGAND BINDING; LYMPH NODE; METASTASIS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PERIODONTAL DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PREGNANCY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THYMOCYTE; THYMUS;

EID: 56549098575     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1443.016     Document Type: Review

References (202)

1. Anderson, D.M. et al. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 : 175 179.
2. Wong, B.R. et al. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272 : 25190 25194.
3. Lacey, D.L. et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 : 165 176.
4. Yasuda, H. et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95 : 3597 3602.
5. Yasuda, H. et al. 1998. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 : 1329 1337.
6. Tsuda, E. et al. 1997. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234 : 137 142.
7. Simonet, W.S. et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 : 309 319.
8. Theill, L.E., W.J. Boyle & J.M. Penninger. 2002. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20 : 795 823.
9. Dougall, W.C. et al. 1999. RANK is essential for osteoclast and lymph node development. Genes. Dev. 13 : 2412 2424.
10. Kong, Y.Y. et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 : 315 323.
11. Li, J. et al. 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97 : 1566 1571.
12. Tan, K.B. et al. 1997. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene. 204 : 35 46.
13. Kwon, B.S. et al. 1998. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J. 12 : 845 854.
14. Lam, J. et al. 2001. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J. Clin. Invest. 108 : 971 979.
15. Ito, S. et al. 2002. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. J. Biol. Chem. 277 : 6631 6636.
16. Wong, B.R. et al. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186 : 2075 2080.
17. Kartsogiannis, V. et al. 1999. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25 : 525 534.
18. Fata, J.E. et al. 2000. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103 : 41 50.
19. Loser, K. et al. 2006. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat. Med. 12 : 1372 1379.
20. Ikeda, T. et al. 2001. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 142 : 1419 1426.
21. Ikeda, T. et al. 2003. Multimerization of the receptor activator of nuclear factor-kappaB ligand (RANKL) isoforms and regulation of osteoclastogenesis. J. Biol. Chem. 278 : 47217 47222.
22. Suzuki, J. et al. 2004. Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem. Biophys. Res. Commun. 314 : 1021 1027.
23. Schlondorff, J., L. Lum & C.P. Blobel. 2001. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. J. Biol. Chem. 276 : 14665 14674.
24. Chesneau, V. et al. 2003. Catalytic properties of ADAM19. J. Biol. Chem. 278 : 22331 22340.
25. Lynch, C.C. et al. 2005. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Can. Cell 7 : 485 496.
26. Hikita, A. et al. 2006. Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J. Biol. Chem. 281 : 36846 36855.
27. Nakagawa, N. et al. 1998. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 253 : 395 400.
28. Hsu, H. et al. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96 : 3540 3545.
29. Chan, F.K. et al. 2000. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288 : 2351 2354.
30. Siegel, R.M. et al. 2000. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288 : 2354 2357.
31. Chan, K.F., M.R. Siegel & J.M. Lenardo. 2000. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 13 : 419 422.
32. Locksley, R.M., N. Killeen & M.J. Lenardo. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 : 487 501.
33. Williamson, E., J.M. Bilsborough & J.L. Viney. 2002. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. J. Immunol. 169 : 3606 3612.
34. Josien, R. et al. 1999. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 162 : 2562 2568.
35. Gonzalez-Suarez, E. et al. 2007. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol. Cell Biol. 27 : 1442 1454.
36. Bucay, N. et al. 1998. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes. Dev. 12 : 1260 1268.
37. Mizuno, A. et al. 1998. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247 : 610 615.
38. Hughes, A.E. et al. 2000. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 24 : 45 48.
39. Whyte, M.P. et al. 2000. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. J. Bone. Miner. Res. 15 : 2330 2344.
40. Whyte, M.P. & A.E. Hughes. 2002. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J. Bone. Miner. Res. 17 : 26 29.
41. Cundy, T. et al. 2002. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum. Mol. Genet. 11 : 2119 2127.
42. Chong, B. et al. 2003. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J. Bone. Miner. Res. 18 : 2095 2104.
43. Inoue, J. et al. 2000. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp. Cell Res. 254 : 14 24.
44. Darnay, B.G. et al. 1998. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J. Biol. Chem. 273 : 20551 20555.
45. Wong, B.R. et al. 1998. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J. Biol. Chem. 273 : 28355 28359.
46. Wong, B.R., R. Josien & Y. Choi. 1999. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J. Leukoc. Biol. 65 : 715 724.
47. Galibert, L. et al. 1998. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J. Biol. Chem. 273 : 34120 34127.
48. Lee, Z.H. et al. 2000. Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappa B. Mol. Pharmacol. 58 : 1536 1545.
49. Lomaga, M.A. et al. 1999. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes. Dev. 13 : 1015 1024.
50. Naito, A. et al. 1999. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes. Cells. 4 : 353 362.
51. Kobayashi, N. et al. 2001. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 20 : 1271 1280.
52. Kobayashi, T. et al. 2003. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 19 : 353 363.
53. Franzoso, G. et al. 1997. Requirement for NF-kappaB in osteoclast and B-cell development. Genes. Dev. 11 : 3482 3496.
54. Iotsova, V. et al. 1997. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3 : 1285 1289.
55. Kanazawa, K. et al. 2003. TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis. J. Bone. Miner. Res. 18 : 443 450.
56. Kanazawa, K. & A. Kudo. 2005. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. J. Bone. Miner. Res. 20 : 840 847.
57. Wada, T. et al. 2005. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat. Med. 11 : 394 399.
58. Karin, M. & A. Lin. 2002. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3 : 221 227.
59. Hayden, M.S. & S. Ghosh. 2008. Shared principles in NF-kappaB signaling. Cell 132 : 344 362.
60. Ruocco, M.G. et al. 2005. I{kappa)B kinase (IKK){beta), but not IKK{alpha), is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J. Exp. Med. 201 : 1677 1687.
61. Novack, D.V. et al. 2003. The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J. Exp. Med. 198 : 771 781.
62. Matsumoto, M. et al. 2000. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J. Biol. Chem. 275 : 31155 31161.
63. David, J.P. et al. 2002. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J. Cell Sci. 115 : 4317 4325.
64. Wagner, E.F. 2002. Functions of AP1 (Fos/Jun) in bone development. Ann. Rheum. Dis. 61 (Suppl 2 ii40 ii42.
65. Yamamoto, A. et al. 2002. Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. J. Bone. Miner. Res. 17 : 612 621.
66. Kenner, L. et al. 2004. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J. Cell Biol. 164 : 613 623.
67. Hotokezaka, H. et al. 2002. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J. Biol. Chem. 277 : 47366 47372.
68. Takayanagi, H. et al. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell. 3 : 889 901.
69. Asagiri, M. et al. 2005. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202 : 1261 1269.
70. Takayanagi, H. 2007. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7 : 292 304.
71. Soriano, P. et al. 1991. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64 : 693 702.
72. Nakamura, I. et al. 1995. Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption. FEBS Lett. 361 : 79 84.
73. Wong, B.R. et al. 1999. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell. 4 : 1041 1049.
74. Sugatani, T., U. Alvarez & K.A. Hruska. 2003. PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility. J. Biol. Chem. 278 : 5001 5008.
75. Takeshita, S. et al. 2002. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat. Med. 8 : 943 949.
76. Mao, D. et al. 2006. PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J. Clin. Invest. 116 : 2869 2879.
77. Mocsai, A. et al. 2004. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl. Acad. Sci. USA 101 : 6158 6163.
78. Takayanagi, H. 2005. Mechanistic insight into osteoclast differentiation in osteoimmunology. J. Mol. Med. 83 : 170 179.
79. Shinohara, M. et al. 2008. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 132 : 794 806.
80. Duran, A. et al. 2004. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev. Cell. 6 : 303 309.
81. Takayanagi, H. et al. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408 : 600 605.
82. Takayanagi, H. et al. 2002. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416 : 744 749.
83. Syed, F. & S. Khosla. 2005. Mechanisms of sex steroid effects on bone. Biochem. Biophys. Res. Commun. 328 : 688 696.
84. Nakamura, T. et al. 2007. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130 : 811 823.
85. Abu-Amer, Y. 2001. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J. Clin. Invest. 107 : 1375 1385.
86. Koseki, T. et al. 2002. Role of TGF-beta family in osteoclastogenesis induced by RANKL. Cell Signal. 14 : 31 36.
87. Arai, F. et al. 1999. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J. Exp. Med. 190 : 1741 1754.
88. Zhang, Y.H. et al. 2001. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 276 : 563 568.
89. De Togni, P. et al. 1994. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264 : 703 707.
90. Rennert, P.D., J.L. Browning & P.S. Hochman. 1997. Selective disruption of lymphotoxin ligands reveals a novel set of mucosal lymph nodes and unique effects on lymph node cellular organization. Int. Immunol. 9 : 1627 1639.
91. Koni, P.A. et al. 1997. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 6 : 491 500.
92. Alimzhanov, M.B. et al. 1997. Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proc. Natl. Acad. Sci. USA 94 : 9302 9307.
93. Matsumoto, M. et al. 1996. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science 271 : 1289 1291.
94. Futterer, A. et al. 1998. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 9 : 59 70.
95. Rennert, P.D. et al. 1998. Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity 9 : 71 79.
96. Sobacchi, C. et al. 2007. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat. Genet. 39 : 960 962.
97. Fu, Y.X. & D.D. Chaplin. 1999. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol. 17 : 399 433.
98. Mebius, R.E. 2003. Organogenesis of lymphoid tissues. Nat. Rev. Immunol. 3 : 292 303.
99. Mebius, R.E., P. Rennert & I.L. Weissman. 1997. Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 7 : 493 504.
100. Kim, D. et al. 2000. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J. Exp. Med. 192 : 1467 1478.
101. Banchereau, J. & R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392 : 245 252.
102. Ingulli, E. et al. 1997. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J. Exp. Med. 185 : 2133 2141.
103. Wang, J. et al. 1999. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98 : 47 58.
104. Josien, R. et al. 2000. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 191 : 495 502.
105. Bachmann, M.F. et al. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 189 : 1025 1031.
106. Kong, Y.Y. et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 : 304 309.
107. Roy, M. et al. 1993. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J. Immunol. 151 : 2497 2510.
108. Quezada, S.A. et al. 2004. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22 : 307 328.
109. Oxenius, A. et al. 1996. CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J. Exp. Med. 183 : 2209 2218.
110. Emery, J.G. et al. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273 : 14363 14367.
111. Yun, T.J. et al. 1998. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J. Immunol. 161 : 6113 6121.
112. Hofbauer, L.C. et al. 1999. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 : 4367 4370.
113. Starr, T.K., S.C. Jameson & K.A. Hogquist. 2003. Positive and negative selection of T cells. Annu. Rev. Immunol. 21 : 139 176.
114. Kyewski, B. & L. Klein. 2006. A central role for central tolerance. Annu. Rev. Immunol. 24 : 571 606.
115. Anderson, M.S. et al. 2002. Projection of an immunological self shadow within the thymus by the aire protein. Science 298 : 1395 1401.
116. Rossi, S.W. et al. 2006. Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium. Nature 441 : 988 991.
117. Rossi, S.W. et al. 2007. RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J. Exp. Med. 204 : 1267 1272.
118. Chin, R.K. et al. 2003. Lymphotoxin pathway directs thymic Aire expression. Nat. Immunol. 4 : 1121 1127.
119. Boehm, T. et al. 2003. Thymic medullary epithelial cell differentiation, thymocyte emigration, and the control of autoimmunity require lympho-epithelial cross talk via LTbetaR. J. Exp. Med. 198 : 757 769.
120. Akiyama, T. et al. 2005. Dependence of self-tolerance on TRAF6-directed development of thymic stroma. Science 308 : 248 251.
121. Anderson, G., P.J. Lane & E.J. Jenkinson. 2007. Generating intrathymic microenvironments to establish T-cell tolerance. Nat. Rev. Immunol. 7 : 954 963.
122. Sakaguchi, S. 2005. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6 : 345 352.
123. Steinman, R.M., D. Hawiger & M.C. Nussenzweig. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21 : 685 711.
124. Mehling, A. et al. 2001. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J. Exp. Med. 194 : 615 628.
125. Green, E.A. & R.A. Flavell. 2000. The temporal importance of TNFalpha expression in the development of diabetes. Immunity 12 : 459 469.
126. Green, E.A., Y. Choi & R.A. Flavell. 2002. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 16 : 183 191.
127. Yun, T.J. et al. 2001. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol. 166 : 1482 1491.
128. Kanematsu, M. et al. 2000. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J. Bone. Miner. Res. 15 : 1321 1329.
129. Waterhouse, P. et al. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270 : 985 988.
130. Feldmann, M., F.M. Brennan & R.N. Maini. 1996. Rheumatoid arthritis. Cell 85 : 307 310.
131. Takayanagi, H. et al. 1997. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem. Biophys. Res. Commun. 240 : 279 286.
132. Panayi, G.S., J.S. Lanchbury & G.H. Kingsley. 1992. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis. Rheum. 35 : 729 735.
133. Bendele, A. et al. 1999. Animal models of arthritis: relevance to human disease. Toxicol. Pathol. 27 : 134 142.
134. Feldmann, M., F.M. Brennan & R.N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14 : 397 440.
135. Campagnuolo, G., B. Bolon & U. Feige. 2002. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis. Rheum. 46 : 1926 1936.
136. Bolon, B., G. Campagnuolo & U. Feige. 2002. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. Cell Mol. Life Sci. 59 : 1569 1576.
137. Muller-Ladner, U., R.E. Gay & S. Gay. 1998. Molecular biology of cartilage and bone destruction. Curr. Opin. Rheumatol. 10 : 212 219.
138. Kouskoff, V. et al. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell 87 : 811 822.
139. Korganow, A.S. et al. 1999. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10 : 451 461.
140. Pettit, A.R. et al. 2001. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 159 : 1689 1699.
141. Keffer, J. et al. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10 : 4025 4031.
142. Mori, H. et al. 2002. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem. Cell Biol. 117 : 283 292.
143. Redlich, K. et al. 2002. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis. Rheum. 46 : 785 792.
144. Romas, E. et al. 2002. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am. J. Pathol. 161 : 1419 1427.
145. Nakashima, T., T. Wada & J.M. Penninger. 2003. RANKL and RANK as novel therapeutic targets for arthritis. Curr. Opin. Rheumatol. 15 : 280 287.
146. Kotake, S. et al. 2001. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis. Rheum. 44 : 1003 1012.
147. Takayanagi, H. et al. 2000. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis. Rheum. 43 : 259 269.
148. Cohen, S.B. et al. 2008. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis. Rheum. 58 : 1299 1309.
149. Oliveri, M.B. et al. 1991. Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford. Hosp. Med. J. 39 : 45 48.
150. Stellon, A.J. et al. 1985. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology 89 : 1078 1083.
151. Piepkorn, B. et al. 1997. Bone mineral density and bone metabolism in diabetes mellitus. Horm. Metab. Res. 29 : 584 591.
152. Seitz, M. & W. Hunstein. 1985. Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus. Ann. Rheum. Dis. 44 : 438 445.
153. Ebeling, P.R. et al. 1998. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J. Bone. Miner. Res. 13 : 1283 1289.
154. Lipton, A. 2006. Future treatment of bone metastases. Clin. Cancer Res. 12 : 6305s 6308s.
155. Teng, Y.T. et al. 2000. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J. Clin. Invest. 106 : R59 R67.
156. Mahamed, D.A. et al. 2005. G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. Diabetes 54 : 1477 1486.
157. Brandt, J. et al. 2000. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis. Rheum. 43 : 1346 1352.
158. Vermeire, K. et al. 1997. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J. Immunol. 158 : 5507 5513.
159. Manoury-Schwartz, B. et al. 1997. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J. Immunol. 158 : 5501 5506.
160. Horwood, N.J. et al. 2001. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J. Immunol. 166 : 4915 4921.
161. Bendixen, A.C. et al. 2001. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc. Natl. Acad. Sci. USA 98 : 2443 2448.
162. Sato, K. et al. 2006. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203 : 2673 2682.
163. Harrington, L.E. et al. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6 : 1123 1132.
164. Park, H. et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6 : 1133 1141.
165. Dong, C. 2006. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat. Rev. Immunol. 6 : 329 333.
166. Kotake, S. et al. 1999. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103 : 1345 1352.
167. Bone, H.G. et al. 2008. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J. Clin. Endocrinol. Metab. 93 : 2149 2157.
168. Lipton, A. et al. 2007. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 25 : 4431 4437.
169. Dougall, W.C. & M. Chaisson. 2006. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Can. Metastasis Rev. 25 : 541 549.
170. McClung, M.R. et al. 2006. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354 : 821 831.
171. Body, J.J. et al. 2006. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Can. Res. 12 : 1221 1228.
172. Lane, N.E. et al. 2006. RANKL Inhibition with Denosumab Decreases Markers of Bone and Cartilage Turnover in Patients with Rheumatoid Arthritis. Arthritis. Rheum. 54 : S225 S226.
173. Dore, R. et al. 2006. Denosumab Increases Bone Mineral Density in Patients With Rheumatoid Arthritis. Arthritis. Rheum. 54 : S240.
174. Cohen, S.B. et al. 2006. RANKL Inhibition with denosumab reduces progression of bone erosions in patients with rheumatoid arthritis: month 6 MRI results. Arthritis. Rheum. 54 : S831 S832.
175. Hofbauer, L.C. et al. 1998. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem. Biophys. Res. Commun. 250 : 776 781.
176. Kido, S. et al. 2003. Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. Bone 32 : 621 629.
177. Kitazawa, S. & R. Kitazawa. 2002. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J. Pathol. 198 : 228 236.
178. Bord, S. et al. 2003. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32 : 136 141.
179. Chen, Q. et al. 2004. Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Horm. Metab. Res. 36 : 674 678.
180. Seriwatanachai, D. et al. 2008. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 42 : 535 546.
181. Brandstrom, H. et al. 1998. Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem. Biophys. Res. Commun. 248 : 454 457.
182. Hofbauer, L.C. et al. 1999. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25 : 255 259.
183. Vidal, O.N. et al. 1998. Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem. Biophys. Res. Commun. 248 : 696 700.
184. Palmqvist, P. et al. 2002. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J. Immunol. 169 : 3353 3362.
185. Horwood, N.J. et al. 1998. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139 : 4743 4746.
186. Takai, H. et al. 1998. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J. Biol. Chem. 273 : 27091 27096.
187. Karsdal, M.A. et al. 2003. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J. Biol. Chem. 278 : 44975 44987.
188. Usui, M. et al. 2008. Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2. J. Bone. Miner. Res. 23 : 314 325.
189. Rubin, J. et al. 2002. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J. Clin. Endocrinol. Metab. 87 : 4273 4279.
190. Min, J.K. et al. 2003. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J. Biol. Chem. 278 : 39548 39557.
191. Vidal, N.O. et al. 1998. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J. Endocrinol. 159 : 191 195.
192. Hofbauer, L.C. et al. 1999. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140 : 4382 4389.
193. Swanson, C. et al. 2006. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology 147 : 3613 3622.
194. Hofbauer, L.C. et al. 2001. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem. Biophys. Res. Commun. 280 : 334 339.
195. Brandstrom, H. et al. 1998. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. Biochem. Biophys. Res. Commun. 247 : 338 341.
196. Murakami, T. et al. 1998. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem. Biophys. Res. Commun. 252 : 747 752.
197. Nakashima, T. et al. 2000. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem. Biophys. Res. Commun. 275 : 768 775.
198. Takami, M. et al. 2000. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. Endocrinology 141 : 4711 4719.
199. Kanatani, M. et al. 2003. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. J. Cell Physiol. 196 : 180 189.
200. Suda, K. et al. 2004. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation. J. Immunol. 172 : 2504 2510.
201. Otsuka, E. et al. 2000. Role of ascorbic acid in the osteoclast formation: induction of osteoclast differentiation factor with formation of the extracellular collagen matrix. Endocrinology 141 : 3006 3011.
202. Nagasawa, T. et al. 2002. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. Clin. Exp. Immunol. 130 : 338 344.